drugset / Trial / NCT05497674

Effects of Rifampicin and Probenecid On The Pharmacokinetic Profile Of Rongliflozin In Healthy Subjects

NCT05497674

Phase 1 Completed 28 enrolled Sunshine Lake Pharma Co., Ltd.
Non-randomizedParallel-groupOpen-labelBasic science

Summary

This is a phase I, open-label, fixed-sequence study in healthy Chinese subjects, performed at a single study centre. Cohort A will assess the Pharmacokinetic (PK) profile of rongliflozin when administered alone and the combination with rifampicin; Cohort B will assess the PK profile of rongliflozin when administered alone and combination with probenecid.

Timeline

Start
2022-02-21
Primary completion
2022-07-22
Completion
2023-02-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Probenecid Small molecule
Subject Rifampin Small molecule
Subject Rongliflozin Small molecule Oral